title: Immediate versus delayed facilitated percutaneous coronary intervention: a pilot study.
abstract: The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied patients have successful reperfusion and TIMI-3 flow and our data may not apply to patients with TIMI 0-2 flow.
authors.affiliation: Division of Cardiology, "Paolo Borsellino," G.F. Ingrassia Hospital, Palermo, Italy. lehdi@tin.it
authors.forename: Pietro
authors.initials: P
authors.lastname: Di Pasquale
authors.forename: Sergio
authors.initials: S
authors.lastname: Cannizzaro
authors.forename: Francesco
authors.initials: F
authors.lastname: Giambanco
authors.forename: Sebastiano
authors.initials: S
authors.lastname: Scalzo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tricoli
authors.forename: Sergio
authors.initials: S
authors.lastname: Fasullo
authors.forename: Salvatore
authors.initials: S
authors.lastname: Paterna
mesh_terms: D000077284:Abciximab; D000328:Adult; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D004562:Electrocardiography; D004608:Eligibility Determination / Q000379:methods; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000628:therapy; D017202:Myocardial Ischemia / Q000401:mortality / Q000628:therapy; D015425:Myocardial Reperfusion / Q000379:methods; D018579:Patient Selection; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077284:Abciximab